Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Nicotinamide phosphoribosyltransferase (NAMPT) inhibitors as therapeutics: rationales, controversies, clinical experience.

Montecucco F, Cea M, Bauer I, Soncini D, Caffa I, Lasigliè D, Nahimana A, Uccelli A, Bruzzone S, Nencioni A. Nicotinamide phosphoribosyltransferase (NAMPT) inhibitors as therapeutics: rationales, controversies, clinical experience. Curr Drug Targets. 2013 Jun 01; 14(6):637-43.

View in: PubMed

Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.